← Back

Wire · regulatory

Faster trials, less red tape. If Europe doesn't act, patients could miss out on new treatments

Published

16 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at euperspectives.eu →

◆ Verified

Fusion42 · 16 November 2026 · Fusion42 review

The European Biotech Act aims to streamline clinical trial approvals in the EU by shortening timelines and harmonising procedures across member states, addressing the EU's declining share in global clinical research especially compared to China. However, stakeholders emphasise that legislative changes must be matched with investments in hospital infrastructure and enforcement to truly speed patient access to innovative treatments.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to prepare for faster clinical trial approvals in Europe but also account for local hospital capacities that can slow patient enrolment. This opens a window to partner with healthcare providers to ensure your trials run smoothly and on schedule.

◆ Coverage

1 source · 16 Nov 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialseuropean-biotech-actpharmaceutical-innovationregulatory-harmonisationhealth-infrastructure